Olympus Corp banner

Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 1 571 JPY 1.58% Market Closed
Market Cap: ¥1.8T

P/FCFE

82.2
Current
336%
Cheaper
vs 3-y average of -34.9

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
82.2
=
Market Cap
¥1.6T
/
Free Cash Flow to Equity
¥21B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
82.2
=
Market Cap
¥1.6T
/
Free Cash Flow to Equity
¥21B

Valuation Scenarios

Olympus Corp is trading above its 5-year average

If P/FCFE returns to its 5-Year Average (21.3), the stock would be worth ¥406.42 (74% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-74%
Maximum Upside
No Upside Scenarios
Average Downside
69%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 82.2 ¥1 571
0%
5-Year Average 21.3 ¥406.42
-74%
Industry Average 31.8 ¥608.45
-61%
Country Average 22.4 ¥427.18
-73%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
JP
Olympus Corp
TSE:7733
1.7T JPY 82.2 20.4
US
Intuitive Surgical Inc
NASDAQ:ISRG
162.6B USD 65.3 56.9
US
Abbott Laboratories
NYSE:ABT
155.4B USD 29 24.8
US
Stryker Corp
NYSE:SYK
112.7B USD 20.7 34.7
IE
Medtronic PLC
NYSE:MDT
102.7B USD 27.3 22.3
US
Boston Scientific Corp
NYSE:BSX
83.8B USD 29.3 23.5
US
Edwards Lifesciences Corp
NYSE:EW
48.8B USD 37 44.5
DE
Siemens Healthineers AG
XETRA:SHL
39.3B EUR 41.4 18.6
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.2B USD 46 42.7
US
Becton Dickinson and Co
NYSE:BDX
42.5B USD 17.6 24.2
US
Resmed Inc
NYSE:RMD
29.9B USD 17.2 20.1

Market Distribution

Higher than 89% of companies in Japan
Percentile
89th
Based on 3 849 companies
89th percentile
82.2
Low
0.1 — 14.9
Typical Range
14.9 — 35
High
35 —
Distribution Statistics
Japan
Min 0.1
30th Percentile 14.9
Median 22.4
70th Percentile 35
Max 736 044 589.7

Olympus Corp
Glance View

Market Cap
1.8T JPY
Industry
Health Care

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes. Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Intrinsic Value
2 138.16 JPY
Undervaluation 27%
Intrinsic Value
Price ¥1 571
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett